Latest News and Press Releases
Want to stay updated on the latest news?
-
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 ...
-
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
-
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in...
-
Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to...
-
CHESTERBROOK, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
-
Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients CHESTERBROOK, Pa.,...
-
PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH...
-
CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
-
FDA considers NDA resubmission a complete Class 2 response Updated guidance on extended cash runway, funding operations into Q1 2021 CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena,...
-
Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs
CHESTERBROOK, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...